InflammamiR-146a and -155 Plasma Levels are Associated with Clinical Efficacy of Risankizumab Treatment in Psoriatic Patients: Pilot Study.
Diotallevi FedericoGiulia MatacchioneGiovanni Marco d'AgostinoHelena GioacchiniAnna CampanatiJacopo SabbatinelliFabiola OlivieriAnnamaria OffidaniPublished in: Dermatology and therapy (2023)
Our results reinforce the notion that specific circulating miRNAs could have clinical relevance as diagnostic/prognostic biomarkers of psoriatic disease and suggest the potential relevance of these miRNAs as biomarkers of treatment response.